Table 2 Characteristics of subjects with advanced RCC with progressors versus nonprogressors on sorafenib treatment
Baseline characteristics* | Progressors,n = 105 (80%) | Nonprogressors,n = 27 (20%) | P |
|---|---|---|---|
Age, years | 58 (49–64) | 63 (55–73) | 0.004 |
Age > 65 years, n (%) | 17 (16) | 11 (42) | 0.007 |
Male, n (%) | 76 (72) | 20 (74) | 1.00 |
Favorable prognosis**, n (%) | 37 (35) | 11 (40) | 0.51 |
Radiation therapy, n (%) | 22 (21) | 5 (19) | 1.00 |
High blood pressure, n (%) | 35 (33) | 9 (35) | 1.00 |
Karnofsky performance status ≥90, n (%) | 66 (63) | 16 (59) | 1.00 |
≥ 2 metastatic sites, n (%) | 38 (36) | 6 (22) | 0.25 |
Hemoglobin, g/dL | 13.9 ± 1.9 | 13.7 ± 1.4 | 0.52 |
Leucocytes, 109/L | 6.3 (5.2–7.9) | 7.1 (5.5–8.9) | 0.36 |
Neutrophils, 109/L | 3.7 (2.6–4.8) | 4.2 (2.7–5.1) | 0.34 |
Platelets, 109/L | 235 (187–311) | 244 (174–294) | 0.70 |
Albumin-adj calcium, mg/dL | 9.5 (9.0–9.9) | 9.5 (9.2–9.8) | 0.78 |
LDH, mg/dL | 176 (150–227) | 180 (162–287) | 0.33 |